Real-world evidence (RWE) is seen as a pioneering method in medicine for obtaining clear results on the risk-benefit profile of drug therapies. Currently, data collection is mainly limited to registry data stored by health insurance companies for billing purposes. It is argued that there is a need for more comprehensive, standardized data collection covering all aspects of drug therapies. As part of this discussion, MEDIKURA Digital Health GmbH, which has developed a unique digital real-world evidence database, will be presented. This innovative platform allows patients to report back their experiences with medication in a standardized way and collects high-quality data from real-world care practice regarding the effects and side effects of drug therapies.
The data generated by MEDIKURA's ImpactMonitor is available in digital form, which makes it easier and cheaper to access and structure. The standardized data sets are available to all affected patients, medical professionals and research companies and support the fast, user-friendly and representative risk-benefit assessment for new drug approvals. This platform provides an important basis for research institutes and drug manufacturers to check the effects and side effects of their products in real time. It also enables monitoring over longer periods of time that are not covered by randomized controlled trials. This contributes significantly to precision medicine, which will become increasingly important in the future, for example in the development of gender- or age-specific drugs.
